Icotinib inhibits the invasion of Tca8113 cells via downregulation of nuclear factor κB‑mediated matrix metalloproteinase expression

Yang,Cailing; Yan,Jianguo; Yuan,Guoyan; Zhang,Yinghua; Lu,Derong; Ren,Mingxin; Cui,Weigang

doi:10.3892/ol.2014.2311

Icotinib inhibits the invasion of Tca8113 cells via downregulation of nuclear factor κB‑mediated matrix metalloproteinase expression

Authors:
- Cailing Yang
- Jianguo Yan
- Guoyan Yuan
- Yinghua Zhang
- Derong Lu
- Mingxin Ren
- Weigang Cui
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital, Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Department of Human Anatomy, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Neurosurgery, The First Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Internal Digestive Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
Published online on: July 4, 2014 https://doi.org/10.3892/ol.2014.2311
Pages: 1295-1298

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Icotinib is an epidermal growth factor receptor tyrosine kinase inhibitor, which has been revealed to inhibit proliferation in tumor cells. However, the effect of icotinib on cancer cell metastasis remains to be explained. This study examines the effect of icotinib on the migration and invasion of squamous cells of tongue carcinoma (Tca8113 cells) in vitro. The results of the Boyden chamber invasion assay demonstrated that icotinib reduced cell invasion, suppressed the protein levels of matrix metalloproteinases (MMPs), MMP‑2 and MMP‑9, and increased the expression of tissue inhibitor of metalloproteinase‑1. In addition, icotinib was found to significantly decrease the protein levels of nuclear factor κB (NF‑κB) p65, which suggested that icotinib inhibits NF‑κB activity. Furthermore, treatment with the NF‑κB inhibitor, pyrrolidine dithiocarbamate, suppressed cell invasion and MMP‑2 expression. These results suggested that icotinib inhibits the invasion of Tca8113 cells by downregulating MMP via the inactivation of the NF‑κB signaling pathways.

View Figures

View References

1	Chen HJ, Lin CM, Lee CY, et al: Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling. Int J Oncol. 43:629–637. 2013.
2	Li F, Li C, Zhang H, et al: VI-14, a novel flavonoid derivative, inhibits migration and invasion of human breast cancer cells. Toxicol Appl Pharmacol. 261:217–226. 2012.
3	Zhou H, Kimura K, Orita T, Nishida T and Sonoda KH: Inhibition by medroxyprogesterone acetate of interleukin-1β-induced collagen degradation by corneal fibroblasts. Invest Ophthalmol Vis Sci. 53:4213–4219. 2012.
4	Kuo PL, Shen KH, Hung SH and Hsu YL: CXCL1/GROα increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic regulation. Carcinogenesis. 33:2477–2487. 2012.
5	Wang Z, Sengupta R, Banerjee S, et al: Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res. 66:7653–7660. 2006.
6	Xu CL, Lu XL, Yan XN, Wang HL and Chen SQ: Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 47:134–138. 2012.(In Chinese).
7	Ko HS, Lee HJ, Kim SH and Lee EO: Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-κB pathways. J Agric Food Chem. 60:4083–4089. 2012.
8	Gan HK, Burgess AW, Clayton AH and Scott AM: Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 72:2924–2930. 2012.
9	Sobhakumari A, Schickling BM, Love-Homan L, et al: NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. Toxicol Appl Pharmacol. 272:736–745. 2013.
10	Li P, Zhang Q, Torossian A, et al: Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer. Int J Radiat Oncol Biol Phys. 83:e391–e397. 2012.
11	Li D, Ji H, Zaghlul S, et al: Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest. 117:346–352. 2007.
12	Yang G, Yao Y, Zhou J and Zhao Q: Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer. Oncol Rep. 27:2066–2072. 2012.
13	Gao Z, Chen W, Zhang X, et al: Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling. Biomed Pharmacother. 67:351–356. 2013.
14	Gu A, Shi C, Xiong L, Chu T, Pei J and Han B: Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin J Cancer Res. 25:90–94. 2013.
15	Zhao Q, Shentu J, Xu N, et al: Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 73:195–202. 2011.
16	Li Y, Xu Q, Zhang Z, Liu S, Shi C and Tan Y: The impact of TGF-β1 on the mRNA expression of TβR I, TβR II, Smad4 and the invasiveness of the JEG-3 placental choriocarcinoma cell line. Oncol Lett. 4:1344–1348. 2012.
17	Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD and Yezierski RP: Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci. 18:3251–3260. 1998.
18	Mu X, Zhang Y, Qu X, et al: Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer. Biomed Res Int. 2013:7263752013.
19	Stark AM, Anuszkiewicz B, Mentlein R, Yoneda T, Mehdorn HM and Held-Feindt J: Differential expression of matrix metalloproteinases in brain- and bone-seeking clones of metastatic MDA-MB-231 breast cancer cells. J Neurooncol. 81:39–48. 2007.
20	Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M and Sato H: Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res. 64:1044–1049. 2004.
21	Sounni NE, Rozanov DV, Remacle AG, Golubkov VS, Noel A and Strongin AY: Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. Int J Cancer. 126:1067–1078. 2010.
22	Tan BK, Adya R, Chen J, Lehnert H, Sant Cassia LJ and Randeva HS: Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab. 96:808–816. 2011.
23	Yan KH, Lee LM, Yan SH, et al: Tomatidine inhibits invasion of human lung adenocarcinoma cell A549 by reducing matrix metalloproteinases expression. Chem Biol Interact. 203:580–587. 2013.
24	Shishodia S and Aggarwal BB: Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression. Oncogene. 25:1463–1473. 2006.
25	Lee CH, Jeon YT, Kim SH and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 29:19–35. 2007.